|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Assistance Publique - Hôpitaux de Paris |
|---|---|
| Information provided by: | Assistance Publique - Hôpitaux de Paris |
| ClinicalTrials.gov Identifier: | NCT00438087 |
Purpose
Facial palsy after surgical removal of cranial base tumors adherent to the nerve can partly be explained by inflammation.
| Condition | Intervention | Phase |
|---|---|---|
|
Facial Palsy |
Drug: methylprednisolone |
Phase III |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Assessment of Corticosteroid Effect in the Prevention of Facial Palsy After Cerebella-Pontine Angle Surgery |
| Estimated Enrollment: | 380 |
| Study Start Date: | March 2007 |
| Estimated Study Completion Date: | May 2009 |
| Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
2: Placebo Comparator
placebo versus methylprednisolone
|
Drug: methylprednisolone
methylprednisolone administrated intra and post operatively
|
|
1: Experimental
placebo versus methylprednisolone
|
Drug: methylprednisolone
methylprednisolone administrated intra and post operatively
|
Facial palsy after surgical removal of cranial base tumors adherent to the nerve can partly be explained by inflammation.
The purpose of this study was to assess the efficiency of corticosteroids to prevent facial palsy after such surgery and to identify the patients that will have the highest benefit from an anti-inflammatory treatment. This study will include patients undergoing surgery for a benign tumor of the cranial base (vestibular schwannoma). The efficiency of high dosage corticosteroids administered intravenously during and after surgery will be evaluated on the facial nerve function in comparison to a placebo. Pre operative and intra operative data will be collected and analysed in order to investigate possible predictive factors of response to the treatment. Introduction: After the surgical removal of a cerebella-pontine angle tumor (mainly vestibular schwannoma), and despite the anatomical integrity of the facial nerve, an immediate or delayed facial palsy may occur. This palsy may be explained by ischemia, edema, inflammation, or a neurotmesis (ruptured axons in an intact nerve sheet). This phenomenon is highly dependent on the size of the tumor. In our preliminary studies, we observed an immediate facial palsy in 16% and a palsy occurring at postoperative day 8 in 23% of the patients operated on for a vestibular schwannoma. Corticosteroids may decrease the inflammation and the edema around the nerve and reduce the incidence of the postoperative facial palsy. Their efficiency has already been demonstrated in idiopathic facial palsy. In a previously published study , a single dose of dexamethasone during surgery did not influence the facial function outcome. But the short period of the treatment do not allow definitive conclusions.
Objectives: The aim of this study is to analyze the effect of a corticosteroid (methyl prednisolone) administered intra- and postoperatively on the incidence of facial palsy after surgery of cerebella-pontine angle tumors and to determine intra operative prognostic factors for the facial function outcome. Material and Methods: A multi center, prospective, randomized, versus placebo, and double-blind study will be undertaken. Four-hundred patients undergoing surgery for a cerebellopontine angle tumor will be included during 23 months. Three university departments of otolaryngology (Hospital BEAUJON, CHU de Bordeaux, CHU de Tours) will participate. The pre operative assessment includes a clinical examination with the assessment of the facial function (in 6 grades according to House and BRACKMANN), an audiometry and a vestibular testing, and a cranial MRI with the classification of tumors in 4 stages according to their size. Patients will be randomized after information and with their consent. During surgery, the degree of nerve stretch (4 stages), the tumor adhesion to the nerve (4 stages) and the stimulation thresholds of the facial nerve with an electromyographic monitoring device (NIM Response 2, XOMED MEDTRONICS, Jacksonville, FL) will be recorded. All cases of facial nerve interruption during surgery will be excluded. In the treated group, one IV injection of methyl prednisolone at 1 mg/kg/day will be administered intra operatively and on postoperative days 1 and 2. The treatment will be continued on days 3 to 7 with the same dosage orally. Subsequently, 0.5 mg/kg/day at days 8 and 8, and 0.25 mg/kg/day at days 10 and 11. The facial function will be assessed on postoperative days 1, 8 and 30 clinically. Expected results: Considering the effect of corticosteroids in the idiopathic facial palsy and the effect of these agents on edema and inflammation, we expect and decrease in the incidence of immediate and delayed postoperative facial palsies. The intra operative stimulation thresholds may indicate a subgroup of patients for which the efficiency of the corticosteroids is higher than in the whole series.
Conclusion : The facial palsy after surgery of cerebellopontine angle tumors is the most frequent and the most significant morbidity. Corticosteroids may decrease the incidence of this complication.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Alexis BOZORG GRAYELI, MD,PhD | +33 (0)-1 40 87 56 29 | alexis.bozorg-grayeli@bjn.aphp.fr |
| France | |
| Assistance Publique Hopitaux De Paris | Recruiting |
| CLICHY, France | |
| Contact: Alexis BOZORG GRAYELLI, MD,PhD +33(0)- 1 40 87 56 29 alexis.bozorg-grayeli@bjn.aphp.fr | |
| Principal Investigator: | Alexis BOZORG GRAYELI, MD,PhD | Assistance Publique - Hôpitaux de Paris |
More Information
| Responsible Party: | Department Clinical Research of Developpement ( Cécile KEDZIA ) |
| Study ID Numbers: | P051072 |
| Study First Received: | February 9, 2007 |
| Last Updated: | April 25, 2008 |
| ClinicalTrials.gov Identifier: | NCT00438087 History of Changes |
| Health Authority: | France: Ministry of Health |
|
Facial palsy Vestibular schwannoma Anti-inflammatory drugs Post surgery of vestibular schwannoma or of cranial base tumors |
|
Mouth Diseases Anti-Inflammatory Agents Neuroma, Acoustic Methylprednisolone Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics Prednisolone acetate Hormones Neuroprotective Agents Acoustic Neuroma Signs and Symptoms Methylprednisolone Hemisuccinate Antineoplastic Agents, Hormonal Facies |
Bell Palsy Neurilemmoma Methylprednisolone acetate Glucocorticoids Facial Paralysis Herpesviridae Infections Virus Diseases Paralysis Facial Nerve Diseases Prednisolone Neurologic Manifestations DNA Virus Infections Stomatognathic Diseases Peripheral Nervous System Agents Bell's Palsy |
|
Mouth Diseases Anti-Inflammatory Agents Disease Attributes Antineoplastic Agents Methylprednisolone Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics Prednisolone acetate Hormones Neuroprotective Agents Signs and Symptoms Pathologic Processes Therapeutic Uses Methylprednisolone Hemisuccinate |
Antineoplastic Agents, Hormonal Facies Bell Palsy Nervous System Diseases Gastrointestinal Agents Methylprednisolone acetate Glucocorticoids Protective Agents Facial Paralysis Pharmacologic Actions Herpesviridae Infections Paralysis Virus Diseases Autonomic Agents Facial Nerve Diseases |